Oncology

The new screening test provides an easier, convenient option for patients seeking to screen themselves for colorectal cancer.

Currently, standard first-line chemotherapy with or without immunotherapy for patients with non-small-cell lung cancer (NSCLC) with HER2 mutations has limited efficacy.

Fedratinib is an orally available, small molecule inhibitor of JAK-2 approved for treatment of myelofibrosis.

Currently, VLS-1488 is being evaluated in a phase 1/2 trial (NCT05902988) in various advanced tumors, including high-grade serous ovarian cancer (HGSOC).

The designation was based on results from the DESTINY-Breast06 trial, evaluating fam-trastuzumab deruxtecan-nxki (Enhertu; AstraZeneca, Daiichi Sankyo) compared with chemotherapy.

The benefits of the daratumumab-based regimen were seen in all patients, including those with high and standard cytogenic risk levels.

Patients exhibited improved disease-free progression with minimal adverse effects.

Zanubrutinib demonstrated sustained responses in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL).

The accelerated course was safe and effective and did not increase complications in patients with breast cancer post-mastectomy undergoing breast reconstruction.

Poorer prognosis was linked to factors such as reduced hemoglobin levels and advanced stage at diagnosis.

Brooke Peters, PharmD, BCOP, discusses a study conducted at American Oncology Network (AON) to evaluate luspatercept dosing for patients with low- to intermediate-risk myelodysplastic syndromes (MDS).

Aaron Adkisson, PharmD, discusses the importance of considering factors such as age, gender, and cardiovascular comorbidities when monitoring and managing cardiotoxic risks in patients with cancer. also emphasizing patient education on recognizing early heart failure symptoms.

These interim trial results support the ongoing phase 3 ITHACA trial.

Ashraf Badros, MBCHB, discussed new data from the AURIGA study presented at the International Myeloma Society 2024 Annual Meeting, happening September 25 through 29 in Rio de Janeiro, Brazil.

The trial is evaluating ciltacabtagene autoleucel (cilta-cel, Carvykti; Johnson & Johnson) in patients with relapsed and lenalidomide-refractory multiple myeloma.

The indication is for adult and pediatric patients aged 2 years and older with advanced or metastatic RET-mutated medullary thyroid cancer (MTC) who require systemic therapy.

Minimal residual disease has been a major topic of discussion during the IMS 2024 Annual Meeting.

Ashraf Badros, MBCHB, discussed findings from the AURIGA study being presented at the International Myeloma Society 2024 Annual Meeting, happening September 25 through 29 in Rio de Janeiro, Brazil.

Promising depth of response and consistent safety profile support the use of talquetamab as a combination agent.

Banerjee also discussed data being presented at the International Myeloma Society 2024 Annual Meeting that he is particularly excited for this year.

Study results showed that Black women with breast cancer were more likely to die across all subtypes, with the disparity varying from 17% to 50% depending on subtype.

The CEPHEUS trial also highlights the importance of minimal residual disease (MRD) as a study end point.

Notably, of the 38 participants who remained on treatment, 37 have switched to less frequent dosing and all have maintained responses.

Using biosimilars and generics as well as getting patients connected with manufacturer copay assistance or grant programs can reduce their out-of-pocket costs.

Clayton Irvine, PharmD, MBA, MS, notes that although these options help to lower the cost of care, quick, widespread implementation remains difficult.

INCA033989 is a monoclonal antibody that selectively targets mutant calreticulin oncogenic function.

These results indicate the combination’s long-term effectiveness in a population with limited treatment options.

Rahul Banerjee, MD, FACP, discussed his presentation at the International Myeloma Society 2024 Annual Meeting on available T cell-directed therapies for myeloma treatment, including CAR T-cell therapies and bispecific antibodies.

Banerjee addressed factors to consider when selecting a regimen, the available treatments in this category, and their key differences.

The decision is based on positive results from the phase 3 LAURA trial.